Proteasomal proteolysis relies on the activity of six catalytically active proteasomal subunits (b1, b2, b5, b1i, b2i and b5i). Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells. In primary leukemia samples, we observed remarkable variability in the amounts of active b1/1i-, b2/2i-and b5/5i-type of subunits, contrasting with their constant protein expression. Bortezomib inhibited b5-and b1-type, but to a lesser extend b2-type of subunits in live primary cells in vitro and in vivo. When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual b1/b5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells. In a panel of cell lines from hematologic malignancies, the ratio between b2-type and (b1 þ b5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity. We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematologic malignancies toward bortezomib. Leukemia (2007) 21, 84-92.
Introduction
With the approval of the proteasome inhibitor bortezomib 1 for clinical use, proteasome inhibition has emerged as a powerful option for the pharmacological treatment of multiple myeloma and possibly other hematologic and non-hematologic malignancies. 2 The proteasome, a barrel-shaped proteolytic complex, is abundant in both the nucleus and cytosol of eucaryotic cells and responsible for the degradation of redundant and misfolded proteins as well as a variety of key regulatory proteins, 3 which is thought to cause increased sensitivity of tumor cells toward the effect of proteasome inhibitors compared to normal cells. [3] [4] [5] The 26S proteasome is the major active proteasome species in mammalian cells and consists of a central 20S core, containing the catalytically active threonine residues, and two 19S regulatory complexes. It contains three different active sites, named b1, b2 and b5, responsible for postglutamyl-, tryptic-or chymotrypsin-like proteolytic activity. Upon stimulation with interferon-g, the production of immunoproteasomes is stimulated, in which active beta subunits are replaced with b1i, b2i and b5i subunits, displaying different substrate-specificities. Currently, little is known about the degree of variability in the activity of the different proteasomal subunits in general, and comparisons between malignant cells from different individual patients or different types of diseases have not been made so far. Proteasome composition and activity is likely to be important for the development of improved therapeutic strategies that interfere with proteasomal proteolysis. The individual activities of proteasome subunits are commonly assessed by measuring the turnover of fluorogenic substrates in cell extracts, 6 ,7 requiring prior cell disruption interfering with regulatory mechanisms that modulate proteasomal activity in intact cells. Importantly, fluorogenic substrates do not differentiate between the constitutive and the immunoproteasome. Cell-based proteasome activity assays have been developed for both mammalian and murine cells based on expressed fluorescent substrates. The activity readout in such assays is influenced by factors such as the rate of protein synthesis and the use of fusion proteins make them unfit for assessing proteasome activity in primary cells. [8] [9] [10] The development of a proteasome-specific, activity-based probe allowed to assess differences in proteasome activity profiles in lysates from human malignant cells. 11 The recent synthesis of a cell-permeable version of this probe (Dansyl-Ahx 3 L 3 VS, abbreviated DALVS 12 ) now for the first time allows us here to probe the activity profile of active proteasome subunits in non-disrupted, viable primary human malignant cells.
Our results demonstrate considerable variability in proteasome activity patterns not reflected by similar changes on the protein level, which do not correlate with a particular type of leukemia. Furthermore, we demonstrate that changes in the proteasomal activity profile indeed characterize acute myeloid leukemia (AML) cells that have acquired resistance toward clinically relevant concentrations of bortezomib. Finally, we provide evidence that the relative ratio of active b2-type to (b1 þ b5)-type of proteasomal subunits mirrors the degree of sensitivity against bortezomib.
Materials and methods
Primary leukemia cells were obtained from peripheral blood of patients at the Department of Hematology and Oncology, University of Tübingen, after written informed consent and approval by the local ethics committee. All patients had high numbers (480%) of leukemic blasts or chronic lymphocytic leukemia (CLL) cells, respectively, in the peripheral blood and had not received specific therapy for at least 3 weeks before collecting the sample. Mononuclear cells were enriched by Ficoll-density gradient centrifugation to a purity of 490% leukemia cells, and immediately used for affinity labeling of proteases. Monocytes were isolated from fresh peripheral blood mononuclear cells (PBMCs) using a Percoll gradient, as described by Greiner et al. 13 The murine T-cell lymphoma line EL-4 and the human B-lymphoblastoid Boleth cell line were grown in 10% fetal calf serum (FCS) supplemented Roswell Park Memorial Institute (RPMI) 1640 medium. RPMI 8226, U266, AMO-1 (myeloma), Jeko, Karpas 1106, SU-DHL-4, Granta 519 (B-non-Hodgkin's lymphoma (NHL)), EHEB (B-acute lymphoblastic leukemia (ALL)), SKW-3 (T-ALL), Raji and DG-75 (Burkitt-NHL) cell lines were obtained from U Keilholz (Department of Hematology, Charite, Campus Benjamin Franklin, Berlin, Germany) and maintained in FCS-supplemented RPMI-1640.
Bortezomib-adapted HL-60 cells (HL-60a) were generated by continuously culturing HL-60 cells in the presence of gradually increasing concentrations of bortezomib (0.5-40 nM) over several weeks. HL-60a cells were maintained in the presence of 20 nM bortezomib. Viability was assessed by removal of aliquots that were mixed with trypan blue dye. Cells that excluded the dye were considered viable and were counted.
The CellTiter 96 MTS-assay (Promega, Mannheim, Germany) was used to determine the cytotoxicity of bortezomib, according to the manufacturer's instructions, and the absorbance of the formazan product was determined in 96-well microplates at 492 nm. The assay measures dehydrogenase enzyme activity found in metabolically active cells.
Affinity labeling of active proteasomes using the proteasomespecific affinity probes Biotin-Ahx 3 L 3 VS (BioALVS) and DALVS was performed as described by Berkers et al. 12 and Kessler et al.
14 Equal amounts of total cellular protein were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by visualization of the labeled species by Western blot, using a rabbit polyclonal dansyl-sulfonamidohexanoyl-specific antibody (Invitrogen, Karlsruhe, Germany) and a horseradish peroxidase-coupled secondary reagent, followed by enhanced chemoluminescence, as described Lautwein et al. 15 Labeling experiments were repeated at least twice in an independent manner, and representative results are displayed. Bortezomib was obtained commercially (Ortho Biotech, Neuss, Germany).
For immunoprecipitation and mass-spectrometry-based analysis of labeled species, 10 8 -10 9 cells were labeled with BioALVS. Immunoprecipitation was performed in cell lysates with streptavidin beads (Sigma, Munich, Germany). To identify the visualized polypetides after SDS-PAGE and coomassie or silver staining with standard protocols, in-gel digestion was performed as described Shevchenko et al. 16 with minor modifications. The protein bands of interest were excised from the gel, washed, digested with trypsin, extracted and analyzed using a Reflex III MALDI-TOF mass spectrometer (Bruker Daltonic, Bremen, Germany), or using nanoelectrospray tandem mass spectrometry on a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer (QSTAR Pulsari, Applied Biosystems/MDS Sciex, Foster City, CA, USA). Database searches (NCBInr) were performed using the MASCOT software from Matrix Science (London, UK) 17 with methionine oxidations as variable modifications based on a probability value of Po0.05.
SDS-PAGE and Western blot was performed on precast 12% gels, as described before by Greiner et al. 13 Anti-proteasome antibodies specific for the respective subunit were purchased from Biomol. For two-dimensional (2D) gel electrophoresis, cells were labeled with DALVS as described, and taken up into isoelectric focusing (IEF)-buffer (9 M urea, 4% 3-[(3-cholamido propyl)-dimethylammonio]-2-hydroxy-1-propanesulfonic acid, 0,5% pharmalyte (Amersham, Freiburg, Germany), 0,4% dithiothreitol (DTT)). IPG strips, pH 3-10, were rehydrated with the samples overnight, followed by IEF gel electrophoresis using the IPG-multiphor device (Pharmacia, Uppsala, Sweden). Consecutively, strips were reduced in DTT, alkylated with iodacetamide and resolved by SDS-PAGE.
Results

Identification of labeled proteasome subunits in primary CLL cells
To identify the activity pattern of proteasome subunits in primary human cells, PBMC freshly isolated from peripheral blood of a CLL patient that did not receive specific therapy (total white blood cell 120 000/ml, 495% lymphocytes), were labeled with the proteasome-specific biotinylated probe BioAhx 3 L 3 VS (BioALVS). Next, active proteasomal subunits, covalently modified by the probe, were isolated by immunoprecipitation using streptavidin-sepharose beads. To control for nonspecific and activity-independent binding, control lysates were heated to 951C for 5 min before addition of the probe in a parallel sample. The polypeptides retrieved were separated by SDS-PAGE and visualized by silver staining (Figure 1a) . Although only trace amounts of active polypeptides were retrieved in the denatured sample, active polypeptides ranging between 20 and 30 kDa were detected in material from CLL cells. Bands were excised and subjected to in-gel tryptic digests, followed by mass spectrometry-based identification of the retrieved species (Table 1) . A 32 kDa band was identified as the proteasomal b2 subunit and a 30 kDa signal representing a doublet of bands, consisted of a (prominent) upper portion that we also identified as b2 proteasomal subunit, and a fainter lower portion representing the b2i subunit. The 20 kDa signal combined polypeptides derived from the b1, b5, b5i and b1i subunits at poor resolution. The b1-derived polypeptides were predominant in the higher molecular weight portion of the band, the b5-and b5i-derived polypeptides were predominant in its central part and the b1i-derived signals were predominantly retrieved from the lower part. The active polypeptides identified in CLL cells were largely consistent with the pattern retrieved from murine EL-4 cells, as observed both by us and others (data not shown and Kessler et al. . Together, these data demonstrated the specificity of labeling by the probe in primary human cells, identified the labeled species and showed that in this particular case of CLL both the constitutive and the immunoproteasome were active.
Effect of bortezomib on proteasome activity in viable human leukocytes in vitro and in vivo
We next aimed at visualizing the effect of bortezomib on the activity profile of proteasomal subunits in live human leukocytes, both in vivo and in vitro. DALVS is a derivative of BioALVS, where the Biotin has been replaced by a dansyl moiety to generate a cell-permeable probe. This compound (DALVS) labels active proteasomal subunits similar to BioALVS, but in addition, owing to its cell-penetrating characteristics, allows targeting of active proteasomal subunits in intact viable cells. 12 Primary monocytes were therefore incubated with increasing concentrations of bortezomib, before adding DALVS to the cell culture, so that only proteasomal subunits that have remained catalytically active are modified by DALVS. In the absence of bortezomib, visualization of the respective active polypeptides by Western blotting against the dansyl moiety of the label revealed a labeling pattern that was similar to that obtained with BioALVS in the CLL sample before (Figure 1b , compare 1a). Preincubation with increasing concentrations of bortezomib showed that the drug selectively targeted active b5 at concentrations ranging from 5 to 10 nM. The activity of b2 subunits was inhibited when bortezomib concentrations of 20 nM were reached. Because the serum concentration of bortezomib is in the 10-20 nM range when the drug is administered at 1.3 mg/m 2 in vivo, we aimed at visualizing the effect of the drug on active proteasome subunits after treatment with bortezomib in vivo. Peripheral blood samples were collected from a patient receiving bortezomib monotherapy for multiple myeloma at 1.3 mg/m 2 immediately before, 1 and 72 h after the bortezomib injection. PBMCs were immediately prepared, followed by labeling of active proteasomes using DALVS. For specificity control, a portion of the pretreatment PBMC was incubated with the proteasome inhibitor 4-hydroxy-3-iodo-2-nitrophenyl-leucinyl-leucinyl-leucine vinyl sulfone (NLVS) before labeling, standard EL-4 cells labeled without prior proteasome inhibition served as an additional control. Before bortezomib treatment, both the 30 kDa double band representing active b2 and b2i, and the 20 kDa signal consisting of active b1, b5 and the respective immunoproteasome subunits were detected in PBMC (Figure 1c ). One hour after bortezomib treatment in vivo, not only the 20 kDa activity signal had disappeared, but also the 30 kDa signal was significantly reduced in intensity. Whereas the 30 kDa signal returned to To ensure the specificity of proteasome labeling with Ahx 3 L 3 VS and identify the active species in labeled intact primary human malignant cells, CLL cells were labeled with BioALVS, either after denaturation (951) or in the native state (RT, room temperature), followed by immunoprecipitation of the labeled species. The active subunits retrieved are visualized after SDS-PAGE and silver staining. Identification was achieved by mass spectrometry of the excised bands after trypsin in-gel digest. (b) Differential effect of bortezomib on proteasome subunit activity in intact primary monocytes. Monocytes were enriched from peripheral blood by Percollgradient centrifugation and incubated with increasing amounts of bortezomib in vitro. Active proteasomal subunits were selectively modified by addition of the cell-permeable affinity probe DALVS to the cell culture. Active proteasome species thus targeted were visualized by SDS-PAGE and Western blot against the dansyl moiety of the probe. (c) Differential effect of bortezomib on proteasome subunit activity in vivo. PBMCs were enriched from the peripheral blood of a patient undergoing bortezomib monotherapy 1.3 mg/m 2 for progressive myeloma before, 1 h after and 72 h after systemic administration of bortezomib, respectively. PBMCs were incubated with DALVS in vitro immediately after purification, and the DALVS-modified active proteasome polypeptides were visualized by Western blot, as described. PBMC from the pretreatment sample preincubated with NLVS 50 mM for 30 min before labeling and murine EL-4 thymoma cells served as internal control. Abbreviation: CLL, chronic lymphocytic leukemia. BioALVS-modified active proteasome polypeptides from CLL cells ( Figure 1 ) were identified after tryptic in-gel digest and sequencing of the emerging peptides using ESI-MSMS, as detailed in Material and methods. Individual polypeptide bands and apparent mass refer to Figure 1 .
Proteasome subunit activity in leukemia M Kraus et al pretreatment intensity 72 h post-treatment, the 20 kDa band still appeared slightly weaker than in the pretreatment control. Thus, 1 h after systemic application of standard dose bortezomib, b1 and b5 proteasomal activity was virtually absent from freshly isolated, viable PBMC, and b2/b2i activity appeared significantly reduced, indicating that bortezomib acts preferentially, but by no means specific on the b5-and b1-type active sites in PBMC in vivo.
Differential activity of proteasome subunits in primary human leukemia cells
To assess proteasomal activity profiles in intact primary human leukemia samples, mononuclear cells isolated from peripheral blood of patients with CLL, ALL or AML (490% lymphocytes or blasts, respectively) were incubated with DALVS. In parallel, a human cell line derived from an Epstein-Barr virus-positive Burkitt lymphoma (BL-30), primary monocytes and EL-4 cells were incubated with DALVS. To reveal the activity-based nature of labeling, the pan-proteasome inhibitor lactacystine was added to intact EL-4 cells before addition of DALVS ( þ Lact.).
After cell lysis, equal amounts of total cellular protein were separated by SDS-PAGE and the labeled active proteasomal subunits were visualized by Western blot (Figure 2a ). Sample 5 represented cells from the same CLL patient as in Figure 1 , so that the identity of the labeled species is directly supported by the sequencing information obtained from Figure 1 / Table 1 . In EL-4 cells, we detected a prominent double band migrating at 30 kDa, previously identified as the b2 and b2i subunits of the proteasome, and a triplet migrating roughly at 20 kDa, consisting of b1, b1i, b5 and b5i subunits, consistent with recently published data that were confirmed by us (data not shown and Kessler et al. 2 and 6) . sample with normal monocytes were assayed for active proteasome subunits using DALVS. Blasts were enriched from peripheral blood to a purity of 480% and incubated with DALVS in vitro, as described, followed by visualization of the respective active proteasomal polypeptides by Western blot. A Western blot against b-actin served as control for protein content. (d) Blast cells were enriched from blood samples taken from peripheral blood of two patients with AML (AML #6, AML #1) at the dates indicated. Cells were labeled with DALVS and active proteasomal polypeptides visualized from equal amounts of total cellular protein, as described before ( þ NLVS: preincubation with NLVS 50 mM 1 h before labeling; PBMC: PBMC from a healthy volunteer).
Proteasome subunit activity in leukemia M Kraus et al Furthermore, the relative activity of the b2 subunit compared to the b2i subunit differed both between different types of leukemia, and within one type of leukemia (compare CLL in lanes 3-5 and ALL in lanes 2 and 6). The activity differences observed by means of affinity labeling were not reflected in the total amounts of polypeptide, as assessed by Western blot (Figure 2b ). The variability in b2 subunit activity was reflected on the polypeptide level only in part (e.g. in samples 3 and 4, but not 6). Labeling patterns in primary human monocytes (lane 7) were similar to those observed in one of the CLL samples (lane 3), suggesting that leukemia cells may not be characterized by aberrant or increased proteasomal activity per se.
To corroborate this high variability in the activity patterns of active proteasome subunits in individual cases of leukemia in a more homogeneous series of samples, we labeled viable AML blasts from five different patients, and visualized active proteasome subunits as before. As was the case for ALL and CLL, highly heterogeneous activity profiles of proteasome subunits were observed between these individual samples. This applied to the b2/b2i subunits as well as to the b1/b5 subunits (Figure 2c ; compare AML #1 vs AML #5) and the relative ratios between both types of active polypeptide signals.
To rule out that the variability in proteasomal activity labeling observed merely mirrored the status of the proteolytic system of cells at a given time rather than a characteristic feature of the cell clone analyzed, we obtained two sequential blood samples in a 12 h interval from a patient with newly diagnosed AML, enriched blast cells to a purity of 480% and performed labeling by DALVS and visualization of active proteasomal subunits as before, in comparison to PBMC from a healthy volunteer. As shown in Figure 2d (left panel), virtually identical patterns of active proteasomal subunits were observed at both time points with cells from the same patient. Note that enrichment of PBMC, labeling with DALVS as well as cell lysis were performed by standard procedures directly after obtaining the blood sample, so that these two samples were prepared independently from each other. After lysis, samples were normalized for equal protein content and resolved side-by-side using SDS-PAGE. The low degree of variability observed here argues against major variations of the active proteasome subunits visualized by DALVS simply owing to limitations in technical reproducibility, as well as against the possibility that the differences observed would mirror different activity states of the proteolytic system at different time points.
Similarly, AML blasts enriched from two consecutive samples obtained within a 4-week interval from one patient were analyzed. The 78-year-old patient was diagnosed with AML and progressed under hydroxyurea, which was therefore terminated 3 weeks before obtaining the first of the two blood samples. Active proteasomal polypeptides were visualized from equal amounts of total protein from AML blasts in these samples, as before, using DALVS. Again, the gross pattern of active polypeptides detected remained constant in this cell population with only minor variability. Thus, major variations in the proteasomal active polypeptide patterns as observed between AML blasts from different patients (compare to Figure 3c) were not observed, when AML blasts from the same patient were repetitively analyzed, either within several hours or weeks.
Resolution of active proteasome subunits by 2D SDS-PAGE
To improve the level of resolution for the analysis of active proteasomes in intact primary cells, and to differentiate between the b1 and b5 subunits, leukemia samples and control cells were resolved by 2D SDS-PAGE after labeling with DALVS ( Figure 3) . The signals retrieved could be attributed to the individual proteasomal subunits based on the sequence information obtained by MALDI-MS after conventional SDS-PAGE (Figure 1) , the mass spectrometry-based analysis of the polypeptides retrieved from EL-4 cells after labeling with BioALVS, streptavidin-mediated pull-down and 2D SDS-PAGE (Figure 3a) , and the published mobility patterns for the respective subunits either in the native state or when labeled with BioALVS. 14, 18 The signals marked by circles represent active isoforms of individual proteasome subunits, as reported. 18 In the CLL sample (compare sample 5, Figure 2a ), all subunits of the constitutive and the immunoproteasome were active. We observed the b2 subunit to be more active than the b2i subunit, confirming the observations made by one-dimensional resolution. A qualitatively very similar 2D activity profile was observed with primary monocytes (sample 7, Figure 2a) , although in this case the b2i subunit was found to be more prominent than the b2 subunit. In both cases, the b5 subunits were only weakly active, but similar in magnitude compared to the activities of the b1 subunits. In the ALL #2 sample (sample 6, Figure 2a) , the b2 activity was higher than the b2i activity, consistent with Figure 2a . Surprisingly, we did not observe detectable amounts of b5 or b5i activity, although the b1 subunits were clearly active. Thus, on a Proteasome subunit activity in leukemia M Kraus et al functional level, this case of ALL did not display the full repertoire of active proteasomal subunits. Whereas the AML #1 sample contained signal intensities for active b2, b2i, b5 and b1 that were roughly comparable to that in monocytes, AML #5 contained considerably higher relative amounts of active b2/b2i species, while active b1 and b5 were at the limit of detection. In summary, viable cells from individual leukemia cases contain diverse relative patterns of active proteasome polypeptides without any obvious preference for individual patterns in a given type of leukemia or leukemic vs benign primary cells.
Bortezomib-resistant AML cells are characterized by increased amounts of active proteasome polypeptides
To assess whether variations in the activity profile of proteasomal subunits in AML cells can be linked to the sensitivity of these cells to proteasome inhibitors such as bortezomib, we aimed at comparing proteasomal activity profiles between two populations of AML cells which mainly differed in their degree of resistance against the drug. To this end, we adapted the human AML cell line HL-60 to bortezomib by incubating it with gradually increasing concentrations of bortezomib over several weeks. At doses over 10 nM bortezomib, this resulted in cytotoxic death of the majority of cells. However, a small fraction of cells recovered after 2-3 weeks and continued to grow in the presence of bortezomib at a rate similar to HL-60 control cells, comparable to an earlier study using the same approach with the proteasome inhibitor NLVS. 19 A gradual increase of the bortezomib concentration to 40 nM did not result in a significant reduction of the growth rate or in cell death in these bortezomib-adapted HL-60 cells (HL-60a). When maintained at clinically relevant bortezomib concentrations (20 nM), HL-60a cells were viable, in stark contrast to the HL-60 parental line, as assessed by trypan blue dye exclusion (Figure 4a ). HL60a cells underwent cytotoxic death at bortezomib 450 nM. When HL-60a cells were cultured in the absence of bortezomib for 7 days and then re-exposed to the drug, they maintained their ability to survive and proliferate in the presence of bortezomib. HL-60 and HL-60a cells did not differ with respect to their sensitivity toward conventional cytotoxic drugs, such as daunorubicin (data not shown).
We performed DALVS-based affinity labeling in HL-60a cells in comparison to the HL-60 parental line to assess the proteasomal activity profile in bortezomib-resistant AML cells (Figure 4b ). Both types of cells were cultured in the absence of bortezomib for 7 days before performing the experiment to wash out residual bortezomib in HL60a cells, and to exclude transient effects that may directly arise from the withdrawal of bortezomib. Comparable results were also obtained with washout periods of several hours or 3 days, respectively. When active proteasomal polypeptides were visualized after labeling with DALVS, HL-60a cells had higher amounts of active b1-and b5-type, as well as b2 and b2i subunits per standardized amount of total protein. Note that not only the total amounts of DALVS-labeled polypeptides increased in HL60a cells, but that also the pattern changed, so that the labeled amounts of the 28 kDa polypeptide identified as the b2 subunit did not increase in HL60a cells, in contrast to the b2i signal, which was higher in HL60a cells. This finding was particularly interesting, because the activity of the b2i polypeptide was not affected by bortezomib up to 40 nM, although the drug efficiently inhibited the 28 kDa b2-type of activity, as shown in Figure 1a . In HL-60 control cells, detectable b1/b5-type of activity was eliminated by preincubation of the cells with 20 nM bortezomib for 1 h, although residual activity was still detected in HL-60a cells under these conditions. By contrast, the vinylsulfone-type of proteasome inhibitor NLVS at 50 mM eliminated all active proteasomal polypeptide signals in both types of cells. In summary, these data demonstrate that the proteasomal activity profile in HL-60 AML cells resistant to proteasome inhibitors differs from that in bortezomib-sensitive HL-60 cells. This applies both to the quantities and activity patterns of the catalytically active subunits, as well as to the degree by which the b1/b5-type of activity could be inhibited using clinically relevant concentrations of bortezomib.
The ratio between b2-and (b1 þ b5)-type of active proteasomal polypeptides mirrors the degree of bortezomib sensitivity
To directly relate bortezomib sensitivity to the proteasomal activity pattern, we compared different types of lymphoid malignant cell lines (myeloma, B-NHL, ALL, Burkitt-NHL) using DALVS labeling in intact cells ( Figure 5, upper panels) . As expected, we again observed a quite heterogeneous activity were labeled with DALVS as described before, either with or without preincubation with the proteasome inhibitors NLVS (50 mM) or bortezomib ( þ Bort; 20 nM). After SDS-PAGE, samples were blotted and active polypeptides were visualized as described before. To score for equal amounts of cellular protein, the same membrane was probed for b-actin by Western blot.
profile between individual cell lines and different biological entities. However, it appeared as if in the myeloma cell lines the signal derived from the bortezomib-sensitive polypetide types b1 and b5 was relatively low, compared to the total active species labeled, whereas this ratio was inverse in cell lines from Burkitt-NHL (compare also BL30 cells, Figure 2a ). This notion was confirmed by densitometry-based quantification of the respective polypeptide signals and calculation of the appropriate ratio (b2-type/(b1 þ b5-type)) relative to the respective b-actin signal (middle panel). Indeed, after this type of assessment, myeloma cells known to be particularly sensitive to bortezomib had the lowest relative (b1 þ b5)-type of proteasomal activity, whereas Burkitt-NHL cells known to resist proteasome inhibition 20 were at the other end of the spectrum. We therefore selected RPMI 8226 myeloma cells as the cell line with the highest b2/(b1 þ b5) ratio, DG-75 Burkitt-NHL cells with the lowest ratio in this respect, and Karpas 1106 B-NHL cells with an intermediate proteasomal labeling ratio, and performed cytotoxicity assays with increasing concentrations of bortezomib ( Figure 5, bottom panel) . Strikingly, RPMI 8226 cells were most sensitive toward the drug, DG-75 cells were least sensitive, whereas the Karpas 1106 cell line showed an intermediate sensitivity. Thus, the relative contribution of proteasomal b1-and b5-type active polypeptides to the overall activity pattern is likely to influence the individual degree of bortezomib sensitivity in hematologic malignancies.
Discussion
Here, we for the first time visualize the differential activity profiles of proteasomes in live primary human cells. The high rate of protein synthesis in most types of malignant cells is likely to result in a high amount of malfunctioning proteins, that are to be disposed of through proteasomal proteolysis. Increased proteasome activity in human cancer cells has been limited to a single study investigating a series of lysates from primary breast cancer samples. 21 Our results do not support the notion of a general upregulation of proteasome activity in malignant cells. In ALL, CLL or AML, proteasome activity appeared to be higher in several, but not all samples when compared to primary monocytes. Ratios between b1/b2/b5 activities in intact primary Figure 5 Low relative b1/b5-type of proteasome activity mirrors bortezomib sensitivity. Top two panels: active proteasome subunits in cell lines from different types of lymphoid malignancies (myeloma, B-NHL, ALL, Burkitt-NHL) were visualized using DALVS as before, together with an immunoblot for b-actin from the same membrane. Middle panel: the signals from the respective active proteasomal subunits after DALVS labeling (panel above) were quantified by densitometry using image-J software, and normalized for equal actin signals, also determined by densitometry. From this the ratio (b2 þ b2i)/(b1 þ b1i þ b5 þ b5i) was calculated and expressed as a bar graph. Bottom panel: RPMI 8226, Karpas 1106 and DG-75 cells were selected as representing cells with low, intermediate or high relative b1/b5-type of activity, as determined above. Cells were incubated with increasing amounts of bortezomib in vitro, and the cytotoxic effect of the drug was determined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay that scores for metabolically active cells.
human cancer cells has not been reported so far. Upon comparison of individual samples, we observed significant variability in the relative activities of the b1, b2 and b5 subunits and in the ratio between active constitutive and immunoproteasome activities. They were observed between different types of leukemia as well as between malignant and benign cells or within one entity of leukemia. These differences observed by activity profiling were not reflected on the protein expression levels, which is consistent with the constant stoichiometry of individual subunits for the structural assembly of the proteasome, implicating the presence of regulatory factors or mechanisms that modulate individual proteasome activities, possibly lost upon cell disruption. Differences in labeling patterns observed in intact cells vs lysates of the same samples 12 support this assumption. Proteasomes are a dynamic cellular component and differ with regard to their subunit composition (constitutive vs immunoproteasomes), but also their cellular distribution (endoplasmic reticulum, nucleus, cytosol) and the presence and nature of regulatory subunits. Concerning the first of these categories, we show that the activity of immunoproteasomes is highly variable not only between different samples of primary leukemia, but also between bortezomib-sensitive and -resistant AML cells. Fluorescent derivatives of DALVS are currently being developed to assess the subcellular localization of bulk proteasomal activity in primary cells. However, we lack appropriate tools to resolve individual active proteasomal subunits with regard to their localization or association with regulatory particles in primary cells not available in literally unlimited quantities.
After systemic administration, bortezomib rapidly exits the plasma compartment, that is, 490% is cleared within 15 min. Application of 1.3 mg/m 2 bortezomib leads to a B60% inhibition of total 20S proteasome activity in peripheral blood 1 h after injection, as determined from peripheral blood cell lysates using a fluorogenic substrate. 22 We here for the first time visualize the differential effect of the drug on individual proteasomal active subunits in intact cells after systemic administration of bortezomib in vivo. Bortezomib treatment reversibly ablates both b1 and b5 activity while reducing b2 proteasomal activity in peripheral blood cells. Given this preference of bortezomib, it seems likely that the variable activity of proteasomal subunits in cancer cells reported here might result in different sensitivity toward the drug, either directly by variations in b5-and b1-type of activity, or via changes in the remaining active subunits that can compensate for inhibited active sites during bortezomib treatment.
To relate the proteasome activity pattern to the bortezomib sensitivity of a given type of cell, we visualized the catalytically active proteasomal polypeptides in intact AML cells that are sensitive or resistant to bortezomib at clinically relevant concentrations. This analysis supports our hypothesis that differences in both the quality and quantities of active proteasomal polypeptides may directly affect bortezomib sensitivity, because HL-60a cells not only showed increased proteasome activity in general, but also changes in the activity pattern of individual polypeptides. In particular, we observed a relative downregulation of the 28 kDa b2 active polypeptide compared to overall activity, and thus a relative upregulation of b1/b5-type active species. Importantly, the upregulation of b1/ b5-type of polypeptides in HL-60a cells resulted in residual detectable activity of these subunits in the presence of 20 nM bortezomib, in contrast to control cells. This has two major implications: first, it suggests that leukemia cells (and possibly other cells) have a regulatory system which can sense the lack of appropriate proteasomal activity and that can correct it, if necessary. This makes the emergence of secondary bortezomib resistance in the clinical setting likely, especially in patients treated for extended times with reduced doses of the drug. Secondly, given the fact that bortezomib mainly targets b1/b5-type of subunits (Figure 1) , it highlights the importance of (residual) b1/b5-type of activity for the survival of cells in the presence of bortezomib.
Concerning the last point, we have compared different types of lymphoid malignancies (myeloma, lymphoma, ALL, Burkittlymphoma) with respect to the ratio between active b2-type and (b1 þ b5)-type of proteasomal polypeptides. Strikingly, in this analysis myeloma cells sensitive toward bortezomib had higher b2-type/(b1 þ b5)-type activity ratios than the other lymphoid cell lines tested. Conversely, Burkitt-lymphoma cells showed the lowest ratio in this respect and were at the same time relatively non-sensitive toward bortezomib, whereas B-NHL and ALL lines showed an intermediate profile in both the bortezomib sensitivity and the proteasomal activity ratio. Together, this suggests that the activity of b1/b5-type proteasomal subunits, either relatively to the remaining active proteasomal polypeptides or as residual activity after bortezomib exposure, represents a key parameter to determine the cytotoxicity of bortezomib.
This is the first study that assesses proteasome activity in viable primary human cancer cells. In summary, our results demonstrate significant variability in the activity profiles of the individual proteasomal subunits between primary cells of human leukemia. Furthermore, we show that secondary resistance toward bortezomib can arise in leukemia cells, characterized by changes in the proteasomal activity profile, and suggest that the activity ratio between b2-type and (b1 þ b5)-type of proteasomal polypeptides may be a key parameter to determine the degree of sensitivity toward bortezomib. This should help to understand the relation between cancer, proteasome activity and the therapeutic effect of proteasome inhibitors like bortezomib.
